Title:Nose-to-brain Drug Delivery System: An Emerging Approach to Chemotherapy-induced Cognitive Impairment
Volume: 13
Issue: 1
Author(s): Shireesha Jannapu Reddy, Srinivas Mutalik, Gollapalle Lakshminarayanashastry Viswanatha, Gautam Kumar, Jeena John, Mallikarjuna Rao Chamallamudi, Arpita Das, Sudip Das and Krishnadas Nandakumar*
Affiliation:
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education,
Manipal, 576104, Karnataka, India
Keywords:
Cancer, nasal, chemotherapy, cognitive impairment, drug-delivery systems, formulation, blood-brain barrier.
Abstract: The rise in global cancer burden, notably breast cancer, emphasizes the need to address
chemotherapy-induced cognitive impairment, also known as chemobrain. Although chemotherapy
drugs are effective against cancer, they can trigger cognitive deficits. This has triggered the exploration
of preventive strategies and novel therapeutic approaches. Nanomedicine is evolving as a
promising tool to be used for the mitigation of chemobrain by overcoming the blood-brain barrier
(BBB) with innovative drug delivery systems. Polymer and lipid-based nanoparticles enable targeted
drug release, enhancing therapeutic effectiveness. Utilizing the intranasal route of administration
may facilitate drug delivery to the central nervous system (CNS) by circumventing first-pass metabolism.
Therefore, knowledge of nasal anatomy is critical for optimizing drug delivery via various
pathways. Despite challenges, nanoformulations exhibit the potential in enhancing brain drug delivery.
Continuous research into formulation techniques and chemobrain mechanisms is vital for developing
effective treatments. The intranasal administration of nanoformulations holds promise for
improving therapeutic outcomes in chemobrain management. This review offers insights into potential
future research directions, such as exploring novel drug combinations, investigating alternative
delivery routes, or integrating emerging technologies to enhance the efficacy and safety of
nanoformulations for chemobrain management.
